Description

AOD9604 (hGH Fragment Peptide)

• AOD9604 is a synthetic peptide derived from the C‑terminal fragment of human growth hormone (hGH 176–191) developed to target fat metabolism and lipolysis without the full spectrum of GH activity.
• Investigational compound studied for effects on adipose tissue, body composition, and metabolic regulation.

Key benefits (research findings)

• Promotes lipolysis and may facilitate reduction of adipose tissue in preclinical and limited clinical studies.
• Designed to act on fat‑metabolism pathways with reduced impact on systemic growth‑hormone effects (e.g., minimal effect on IGF‑1 at studied doses).
• May support improvements in body composition when combined with diet and exercise in experimental settings.
• Useful as a research tool to investigate adipocyte signaling, metabolic modulation, and peptide‑based interventions for obesity/metabolic research.

Primary uses

• Preclinical and translational research into obesity, adipose biology, metabolic dysfunction, and related therapeutic strategies.
• Early‑phase human research under controlled clinical protocols focused on fat‑loss endpoints, safety, and pharmacodynamics.
• Mechanistic studies probing lipolytic pathways and peptide fragment pharmacology.

Suggested use (research context)

• Use only per institutional review board (IRB)/ethics‑approved protocols and supplier recommendations. Common research routes include subcutaneous administration in animal models or protocol‑defined dosing in human trials.
• Perform dose‑finding and safety assessments in pilot studies before broader application; include appropriate controls and monitoring.
• Combine with standardized diet/exercise protocols when studying body composition endpoints.

Safety and storage

• Investigational: long‑term human safety and efficacy data remain limited. Avoid human exposure outside approved clinical trials.
• Potential adverse effects observed in peptide studies include injection‑site reactions and transient metabolic changes; monitor glucose and metabolic markers as appropriate.
• Contraindications and precautions depend on individual health status—consult institutional clinical investigators and safety officers.
• Handle with laboratory PPE and aseptic technique. Store lyophilized peptide per supplier instructions (commonly refrigerated or frozen for long‑term storage). Reconstitute with sterile diluent, aliquot, and minimize freeze–thaw cycles. Protect from moisture and light and dispose of per institutional hazardous‑waste protocols.

Quick facts

• Mechanism: modified hGH C‑terminal fragment aimed at stimulating fat‑metabolism pathways and lipolysis without broad GH receptor activation.
• Status: investigational; regulatory approval and clinical availability vary by region—use only within approved research or clinical frameworks.
• Procurement: available to research entities from legitimate peptide suppliers with appropriate institutional approvals.

Research Use Only Disclaimer

Products sold by SoCo Peptides are intended strictly for laboratory research purposes only.

These compounds are not intended for human consumption, veterinary use, household use, cosmetic use, or therapeutic application. They are not drugs, foods, or dietary supplements and have not been evaluated or approved by the FDA.

By purchasing from this website, the customer represents that they are a qualified researcher or laboratory professional and understand the risks associated with handling research materials.

All products must be handled by trained professionals in appropriate research facilities and in accordance with all applicable laws and regulations.

SoCo Peptides makes no guarantees or claims regarding safety, effectiveness, or medical benefit.